Pembrolizumab Treatment for Kidney Cancer

Pembrolizumab treatment for kidney cancer, particularly advanced renal cell carcinoma (RCC), represents a significant advancement in immunotherapy. Approved by the U.S. Food and Drug Administration (FDA) in 2019, it is specifically indicated in combination with axitinib for the first-line treatment of advanced RCC, marking a substantial progress in managing this type of cancer.

Pembrolizumab is a monoclonal antibody functioning as an immune checkpoint inhibitor. It targets the programmed death-1 (PD-1) receptor on T cells, a crucial component of the immune response. By inhibiting PD-1, pembrolizumab prevents cancer cells from using PD-1 pathways to escape immune detection, thereby boosting the immune system's ability to combat cancer cells.

This drug, in combination with axitinib, a tyrosine kinase inhibitor, is indicated as a first-line treatment for patients with advanced RCC. This combination is particularly effective for patients who have not previously received therapy for advanced disease.

Administered via intravenous (IV) infusion in a clinical setting, pembrolizumab's dosage and schedule are tailored to the patient's specific condition and response to treatment. The combination with oral axitinib is designed to optimize treatment efficacy.

Clinical trials have demonstrated significant improvements in progression-free and overall survival for patients treated with pembrolizumab and axitinib, compared to sunitinib, a standard treatment for advanced RCC. The combination therapy has shown higher response rates and delayed disease progression in patients with advanced RCC.

Common side effects of pembrolizumab include fatigue, diarrhea, liver enzyme elevations, rash, and hypothyroidism. Like other immunotherapies, pembrolizumab can cause immune-related adverse effects (irAEs) such as colitis, hepatitis, and pneumonitis. Managing these side effects involves close monitoring, dose adjustments, and possibly the use of corticosteroids or other immunosuppressive drugs for severe irAEs.

Patients receiving pembrolizumab require frequent monitoring to manage side effects and evaluate the treatment's effectiveness. Treatment with pembrolizumab necessitates a coordinated approach, often involving oncologists, nurses, and other specialists.

The introduction of pembrolizumab for advanced RCC, especially when combined with axitinib, has provided a new and effective option for patients with this challenging form of cancer. This approval underscores the growing role of immunotherapy in cancer treatment, offering improved outcomes and the potential for extended survival in advanced RCC.

Reference

Rini BI, Plimack ER, Stus V, et al. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 2019;380(12):1116-1127.

Comments

Post a Comment

Popular posts from this blog

What Is Kidney Cancer?

Kidney cancer is a type of cancer that starts in the kidneys, the two bean-shaped organs located on either side of the spine, just below the rib cage. The kidneys play a crucial role in filtering blood, removing waste products and excess fluids, and producing urine. Understanding kidney cancer is vital for early detection and effective treatment. This comprehensive overview covers the basics of kidney cancer, including its types, causes, symptoms, and treatment options. What is Kidney Cancer? Kidney cancer occurs when cells in the kidney grow uncontrollably, forming a tumor. In most cases, kidney cancer originates in the lining of the tiny tubes inside the kidneys (renal tubules). The cancer can spread (metastasize) to other parts of the body if not detected early. There are several types of kidney cancer, with the most common being renal cell carcinoma (RCC). Other less common types include urothelial carcinoma and Wilms tumor, which typically affects children. Causes and Risk Factors
Read more

How is Kidney Cancer Diagnosed?

Understanding how kidney cancer is diagnosed is crucial for anyone seeking information about this disease, which starts in the kidneys—the organs responsible for filtering waste from the blood and creating urine. Early detection can significantly impact treatment outcomes, making awareness of the diagnostic process essential. This guide aims to break down the steps and methods used by healthcare professionals to diagnose kidney cancer, ensuring you are well-informed about this critical phase of cancer care. Recognizing the Symptoms Often, kidney cancer does not cause noticeable symptoms in its early stages. However, as the cancer grows, symptoms such as blood in the urine (hematuria), lower back pain on one side (not caused by injury), a mass or lump on the side or lower back, fatigue, unexplained weight loss, or fever may prompt a visit to the doctor. Recognizing these signs and seeking medical advice is the first step in the diagnostic process. Initial Consultation and Physical Exam
Read more

Prostate Cancer: An Overview

Image
Prostate cancer is a concern for men, particularly those over 50 or with a family history of the disease. Understanding prostate cancer is crucial for early detection and effective management. While the prospect of prostate cancer can be daunting, advancements in medical science have made it a highly manageable condition, especially when diagnosed early. In this article, I provide an overview of prostate cancer. Prostate cancer: Location of the prostate gland . Source . What is Prostate Cancer? Prostate cancer is a type of cancer that occurs in the prostate, a small walnut-shaped gland in men that produces the seminal fluid that nourishes and transports sperm. This cancer is one of the most common types affecting men and tends to grow slowly, often confined to the prostate gland initially, where it may not cause significant harm. However, while some types of prostate cancer grow slowly and may need minimal or no treatment, others are aggressive and can spread quickly and become metasta
Read more

What is the Survival Rate for Bladder Cancer?

The survival rate for bladder cancer depends on various factors, particularly the stage of the cancer. The survival rate is an estimate of the percentage of people who survive a certain amount of time after being diagnosed with the same type and stage of cancer. Typically, survival rates for bladder cancer, and indeed for all cancers, are presented in terms of 5-year or 10-year intervals.  A 5-year survival rate, for example, refers to the percentage of people who live at least five years after their cancer diagnosis. It is crucial to understand that these rates are based on the outcomes of large numbers of people who had the disease in the past, but they cannot predict what will happen in any individual case.  According to the American Cancer Society, the relative 5-year survival rates for bladder cancer are as follows:  Stage 0: The 5-year survival rate is around 98%.  Stage I: The 5-year survival rate is approximately 88%. Stage II: The 5-year survival rate is about 63%.  Stage III:
Read more

Can Bladder Cancer be Prevented?

No, bladder cancer cannot be entirely prevented. It is a fact of life that some people are simply unfortunate enough to develop bladder cancer. Adopting a lifestyle that avoids tobacco smoking, maintains a balanced diet, limits exposure to harmful chemicals, ensures adequate hydration, and involves being mindful of certain medications and supplements can contribute to a healthier life. However, these measures do not necessarily prevent bladder cancer.
Read more

What are the Risk Factors for Bladder Cancer?

Bladder cancer is a condition that can affect anyone, but certain factors significantly increase the risk of developing this disease. Understanding these risk factors is crucial for prevention and early detection. This article provides a detailed overview of the primary risk factors associated with bladder cancer, offering insights that may help individuals reduce their risk. Smoking and Bladder Cancer Smoking is the single most significant risk factor for bladder cancer. The harmful chemicals in tobacco smoke are absorbed into the bloodstream and eventually filtered by the kidneys into the urine. These carcinogens can damage the lining of the bladder, which over time increases the likelihood of cancerous mutations. Smokers are at least three times more likely to develop bladder cancer than non-smokers, making smoking cessation a critical preventative measure. Occupational Exposure to Chemicals Certain occupations that involve exposure to carcinogenic chemicals significantly increase t
Read more

Urology Cancers Blog Disclaimer

Urology Cancers blog offers general information about urological conditions, including urologic cancers. The content provided is intended solely for informational purposes. Although every effort is made to ensure the accuracy of the information at the time of publication, the potential for errors does exist. By engaging with the content of this blog in any form, such as commenting, sharing, visiting, or reading this blog, you acknowledge and agree that the information presented, including any linked material, should not be considered as a substitute for professional medical advice. Further, you agree not to use this information to self-diagnose or treat any medical conditions or diseases on yourself or others. In case you suspect or know of a medical condition or disease, seeking the advice of an appropriately qualified healthcare professional could help you with the best course of action. You should not disregard professional medical advice or delay in seeking it due to something you
Read more

Is Bladder Cancer Hereditary?

When it comes to bladder cancer, one common question is whether the disease can be inherited. Understanding the genetic factors associated with bladder cancer can help individuals assess their risk and take preventive measures. This article explores the hereditary nature of bladder cancer, explaining how genetics may influence the risk and discussing what this means for families with a history of the disease. The Role of Genetics in Bladder Cancer Bladder cancer, like many other types of cancer, can sometimes appear to "run in families." However, most cases of bladder cancer are not directly inherited in a simple genetic pattern. Instead, what is often inherited is not the cancer itself but a susceptibility to factors that increase the risk of developing the disease. Genetic Mutations and Bladder Cancer Certain genetic mutations can increase the risk of bladder cancer. Researchers have identified changes in specific genes that may enhance an individual's susceptibility to
Read more

Pembrolizumab for Renal Cell Carcinoma

Image
Pembrolizumab is a checkpoint inhibitor that belongs to a class of drugs called monoclonal antibodies. Pembrolizumab binds to a protein called programmed cell death-1 (PD-1) on the surface of immune cells called T cells, and prevents it from interacting with another protein called programmed cell death-ligand 1 (PD-L1) on the surface of cancer cells. This interaction normally inhibits the activation and function of T cells, allowing cancer cells to escape immune surveillance and attack. By blocking this interaction, pembrolizumab enhances the ability of T cells to recognize and kill cancer cells. Pembrolizumab, used in the treatment of renal cell carcinoma, is a checkpoint inhibitor and belongs to the class of drugs known as monoclonal antibodies. Source . Pembrolizumab and Axitinib for Renal Cell Carcinoma Pembrolizumab has been approved by the FDA for the treatment of renal cell carcinoma in different settings. In 2019, pembrolizumab was approved in combination with axitinib for the
Read more